SINGAPORE, Sept. 04, 2025 — EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a leading Singapore-based non-invasive healthcare provider in Asia, primarily focusing on Singapore, Malaysia, and China, today announced it has secured distribution rights for T-cell immunotherapies in Malaysia. These therapies are developed by Shenzhen Inno Immune Co. Ltd. (“Shenzhen Inno”), a Chinese developer of autologous cellular therapeutic and customized medicines for a broad spectrum of diseases. The T-cell immunotherapies are designed to restore and rebuild the body’s natural defenses.
This initiative represents EUDA’s second significant step into advanced cell therapy this year, following its April 2025 distribution partnership with Guangdong Cell Biotech Co., Ltd., a prominent leader in autologous stem cell therapies in China. Taken together, these strategic actions highlight EUDA’s accelerated commitment to the regenerative and longevity medicine space, reinforcing its dedication to providing science-driven, non-invasive solutions for addressing aging and chronic conditions.
Under the terms of the agreement, Guangdong Key Lock Health Management Co., Ltd. (“Keylock”), a long-term strategic partner to both Shenzhen Inno and EUDA, and a distributor of Shenzhen Inno’s stem cell therapies and regenerative medicine, has granted CK Health Plus Sdn Bhd, a wholly-owned subsidiary of EUDA, the right to market and sell Shenzhen Inno’s T-cell immunotherapies to EUDA customers within Malaysia.
The T-cell immunotherapy package will retail at USD 8,000 per treatment, which is a fraction of the customary cost in other regional markets. This pricing approach reflects a clinically advanced, personalized method for long-term immune system support, while simultaneously making cutting-edge immunotherapy more accessible across Malaysia by addressing the historical cost barriers that have previously limited access to such treatments.
Shenzhen Inno contributes substantial scientific and institutional backing to this partnership, including:
• A GMP-standard cell and virus preparation center, ensuring pharmaceutical-grade quality
• Recognition under China’s prestigious “Peacock Plan” project for elite innovation teams
• Strategic backing from leading venture capital firm Sequoia Capital during its angel investment round
• Establishment of a Postdoctoral Innovation Practice Base to foster high-level talent development
Mr. Alfred Lim, CEO of EUDA, commented, “This strategic expansion into T-cell immunotherapy represents a pivotal moment for EUDA as we continue to diversify our healthcare portfolio and deliver innovative solutions to our customers. By working with Shenzhen Inno and Keylock, we’re offering world-class immune-enhancing therapies to Malaysians at a fraction of traditional costs, furthering our mission to transform the health and wellness landscape in the region, creating significant growth potential going forward.”
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia, with a strategic focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, particularly within the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region, which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also operates a Singapore-based property management business.
Forward Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements typically use forward-looking words, such as “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose,” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA and Shenzhen Inno, as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact:
Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail:
